PURPOSE: Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in patients with CNL and aCML, irrespective of CSF3R mutation status. METHODS: We conducted a phase II study of ruxolitinib in 44 patients (21 CNL and 23 aCML). The primary end point was overall hematologic response rate (ORR) by the end of 6 continuous 28-day cycles for the first 25 patients enrolled. We considered a response as either partial (PR) or complete response (CR). We expanded accrual to 44 patients to increase our ability to evaluate secondary end points, including grade ≥ 3 adverse events, spleen volume, symptom assessment, genetic correlates of response, and 2-year survival. RESULTS: ORR was 32% for the first 25 enrolled patients (8 PR [7 CNL and 1 aCML]). In the larger cohort of 44 patients, 35% had a response (11 PR [9 CNL and 2 aCML] and 4 CR [CNL]), and 50% had oncogenic CSF3R mutations. The mean absolute allele burden reduction of CSF3R-T618I after 6 cycles was greatest in the CR group, compared with the PR and no response groups. The most common cause of death is due to disease progression. Grade ≥ 3 anemia and thrombocytopenia were observed in 34% and 14% of patients, respectively. No serious adverse events attributed to ruxolitinib were observed. CONCLUSION: Ruxolitinib was well tolerated and demonstrated an estimated response rate of 32%. Patients with a diagnosis of CNL and/or harboring CSF3R-T618I were most likely to respond.
PURPOSE:Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in patients with CNL and aCML, irrespective of CSF3R mutation status. METHODS: We conducted a phase II study of ruxolitinib in 44 patients (21 CNL and 23 aCML). The primary end point was overall hematologic response rate (ORR) by the end of 6 continuous 28-day cycles for the first 25 patients enrolled. We considered a response as either partial (PR) or complete response (CR). We expanded accrual to 44 patients to increase our ability to evaluate secondary end points, including grade ≥ 3 adverse events, spleen volume, symptom assessment, genetic correlates of response, and 2-year survival. RESULTS: ORR was 32% for the first 25 enrolled patients (8 PR [7 CNL and 1 aCML]). In the larger cohort of 44 patients, 35% had a response (11 PR [9 CNL and 2 aCML] and 4 CR [CNL]), and 50% had oncogenic CSF3R mutations. The mean absolute allele burden reduction of CSF3R-T618I after 6 cycles was greatest in the CR group, compared with the PR and no response groups. The most common cause of death is due to disease progression. Grade ≥ 3 anemia and thrombocytopenia were observed in 34% and 14% of patients, respectively. No serious adverse events attributed to ruxolitinib were observed. CONCLUSION:Ruxolitinib was well tolerated and demonstrated an estimated response rate of 32%. Patients with a diagnosis of CNL and/or harboring CSF3R-T618I were most likely to respond.
Authors: Francisco Cervantes; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Andres Sirulnik; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard S Levy; Francesco Passamonti; Tiziano Barbui; Giovanni Barosi; Claire N Harrison; Laurent Knoops; Heinz Gisslinger Journal: Blood Date: 2013-10-30 Impact factor: 22.113
Authors: Zohra Nooruddin; Nicholas Miltgen; Qi Wei; Jeffrey Schowinsky; Zengang Pan; Jennifer Tobin; Enkhtsetseg Purev; Jonathan A Gutman; William Robinson; Daniel A Pollyea Journal: Haematologica Date: 2017-02-16 Impact factor: 9.941
Authors: Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245
Authors: M Koldehoff; D W Beelen; R Trenschel; N K Steckel; R Peceny; M Ditschkowski; H Ottinger; A H Elmaagacli Journal: Bone Marrow Transplant Date: 2004-12 Impact factor: 5.483
Authors: Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles A Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia M Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List Journal: Blood Date: 2007-09-24 Impact factor: 22.113
Authors: Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman Journal: Blood Date: 2016-04-11 Impact factor: 22.113
Authors: S Rohrabaugh; M Kesarwani; Z Kincaid; E Huber; J Leddonne; Z Siddiqui; Y Khalifa; K Komurov; H L Grimes; M Azam Journal: Leukemia Date: 2016-12-27 Impact factor: 11.528
Authors: Natasha Szuber; Christy M Finke; Terra L Lasho; Michelle A Elliott; Curtis A Hanson; Animesh Pardanani; Ayalew Tefferi Journal: Blood Cancer J Date: 2018-02-15 Impact factor: 11.037
Authors: Aubrie Eaton; Victor Wong; Deborah Schiff; Eric Anderson; Hilda Ding; Edmund V Capparelli; Deb Determan; Dennis John Kuo Journal: J Pediatr Pharmacol Ther Date: 2022-02-09
Authors: Maria Eduarda Couto; Susana Bizarro; Domingos Sousa; Nelson Domingues; Isabel Oliveira; Gabriela Martins; Manuel R Teixeira; Mário Mariz Journal: Case Rep Hematol Date: 2020-12-21
Authors: Evandro D Bezerra; Terra L Lasho; Christy M Finke; Antoine N Saliba; Michelle A Elliott; Animesh D Pardanani; Naseema Gangat; Abhishek A Mangaonkar; Rhett P Ketterling; Ayalew Tefferi; Eric Solary; Mrinal M Patnaik Journal: Blood Cancer J Date: 2021-03-11 Impact factor: 11.037
Authors: Anthony M Hunter; Hannah Newman; Amy E Dezern; David P Steensma; Sandrine Niyongere; Gail J Roboz; Qianxing Mo; Onyee Chan; Aaron Gerds; David A Sallman; William Dominguez-Viqueira; Christopher Letson; Maria E Balasis; Markus Ball; Traci Kruer; Hailing Zhang; Jeffrey E Lancet; Alan F List; Mikkael A Sekeres; Rami S Komrokji; Eric Padron Journal: Clin Cancer Res Date: 2021-07-12 Impact factor: 12.531